Pien Huang
Pien Huang is a health reporter on the Science desk. She was NPR's first Reflect America Fellow, working with shows, desks and podcasts to bring more diverse voices to air and online.
She's a former producer for WBUR/NPR's On Point and was a 2018 Environmental Reporting Fellow with The GroundTruth Project at WCAI in Cape Cod, covering the human impact on climate change. As a freelance audio and digital reporter, Huang's stories on the environment, arts and culture have been featured on NPR, the BBC and PRI's The World.
Huang's experiences span categories and continents. She was executive producer of Data Made to Matter, a podcast from the MIT Sloan School of Management, and was also an adjunct instructor in podcasting and audio journalism at Northeastern University. She worked as a project manager for public artist Ralph Helmick to help plan and execute The Founder's Memorial in Abu Dhabi and with Stoltze Design to tell visual stories through graphic design. Huang has traveled with scientists looking for signs of environmental change in Cameroon's frogs, in Panama's plants and in the ocean water off the ice edge of Antarctica. She has a degree in environmental science and public policy from Harvard.
-
The treatments were highly popular earlier in the pandemic. One by one, they got knocked out by more convenient, less expensive treatment options, and new COVID variants. -
For those at high risk, Pfizer's antiviral drug helps stave off severe COVID-19. Now research suggests it may also reduce their chances of long COVID.
-
The updated recommendations seek to course correct after guidelines from 2016 were criticized for harshly limiting access to needed pain medication.
-
Early fears of an escalating outbreak have not come to pass. Scientists are finding that the virus needs a very particular set of circumstances to spread effectively.
-
Dr. Demetre Daskalakis is steering the U.S. monkeypox response. A month into the job, he sees signs of success, but there's still more to be done.
-
Rates of new cases are declining in major cities, suggesting public health campaigns are working. But the spread
-
Pfizer has submitted data on its bivalent COVID-19 booster shot that specifically targets the latest omicron subvariants. If authorized, the company says the shots could be ready as soon as September.
-
Missteps and delays have hampered the U.S. effort to vaccinate people against monkeypox. Now state health officials and community members are trying to adapt to a controversial "dose sparing" plan.
-
Revised guidance from the Centers for Disease Control and Prevention looks to minimize COVID-19's disruption of daily life while conceding that the pandemic isn't over.
-
The Biden administration is allowing the shot to be given between layers of skin — a method that only requires a fifth of the full dose — in order to increase vaccinations and slow the outbreak.
